Fast Pharma News Round-Up

Top UK doctors warn Boris Johnson that no-deal Brexit would cause key cancer therapy supply shortages

Representatives from the Royal College of Radiologists, the British Nuclear Medicine Society and the UK Radiopharmacy Group have written a letter to Prime Minister Boris Johnson to inform them on their concerns over the nation’s ability to deliver cancer treatments to patients if the UK crashes out of the EU without a deal. (Source: pharmafile.com)

Alzheimer’s blood test ‘one step closer’

Progress has been made with the detection of Alzheimer’s disease. Researchers claim they can accurately identify people on track to develop the disease, before symptoms appear. US scientists were able to use levels of a protein in the blood to help predict its build-up in the brain. (Source: bbc.co.uk)

RCGP warns new PM that we ‘cannot risk no-deal disruption’

The chair of the Royal College of General Practitioners, Helen Stokes-Lampard, has written a letter to new prime minister Boris Johnson outlining the College’s concerns around protection of the NHS, and no-deal Brexit among other things. (Source: pharmatimes.com)

AZ presents strong H1 financial results

AstraZeneca (AZ) has announced that in its first half of 2019 product sales grew 12% to $11,183m, including an acceleration in second-quarter product sales to $5,718m. (Source: pharmatimes.com)

Pfizer and Mylan want to create a generic-drug giant

Pfizer’s off-patent division, Upjohn is set to merge with the large but struggling generic-drug firm, Mylan. The all-stock transaction, announced on July 29th, would create the world’s largest generics firm by revenue, with an enterprise value of $50bn. (Source: economist.com)